Dynavax Technologies Corp's stock surged by 39.62% in pre-market trading, reaching a 52-week high, following the announcement of its acquisition by Sanofi.
The acquisition agreement involves Sanofi acquiring Dynavax for $15.50 per share, totaling approximately $2.2 billion, which significantly enhances Sanofi's market position in adult immunization. This strategic move integrates Dynavax's marketed adult hepatitis B vaccine HEPLISAV-B and a promising shingles vaccine candidate into Sanofi's portfolio, addressing significant unmet public health needs and expanding its market share. The deal is expected to close in the first quarter of 2026, reflecting Sanofi's commitment to the future vaccine market.
This acquisition not only boosts Dynavax's stock price but also positions Sanofi to better meet the health needs of nearly 100 million unvaccinated adults in the U.S., indicating a strong strategic investment in the adult immunization sector.
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 20.50 USD with a low forecast of 16.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 20.50 USD with a low forecast of 16.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.480
Low
16.00
Averages
20.50
High
25.00
Current: 15.480
Low
16.00
Averages
20.50
High
25.00
Citizens JMP
Roy Buchanan
Outperform
maintain
$31 -> $32
2025-08-08
Reason
Citizens JMP
Roy Buchanan
Price Target
$31 -> $32
AI Analysis
2025-08-08
maintain
Outperform
Reason
Citizens JMP analyst Roy Buchanan raised the firm's price target on Dynavax to $32 from $31 and keeps an Outperform rating on the shares. Dynavax continues to focus on priorities in HEPLISAV-B, business development, and the pipeline with the board battle behind it, the analyst tells investors in a research note.
Goldman Sachs
Paul Choi
Strong Sell
Maintains
$12 → $10
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$12 → $10
2025-04-17
Maintains
Strong Sell
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$31
2025-02-21
Reason
HC Wainwright & Co.
Edward White
Price Target
$31
2025-02-21
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Jason Butler
Buy
Maintains
$29 → $33
2025-02-21
Reason
Citizens Capital Markets
Jason Butler
Price Target
$29 → $33
2025-02-21
Maintains
Buy
Reason
Citizens JMP raised the firm's price target on Dynavax to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported fiscal 2024 results in line with January's preannouncement, and management remains optimistic on the potential for bringing in value-add, late-stage assets in the infectious disease space as the best way to maximize the value of its hepatitis B vaccine, HEPLISAV-B, the analyst tells investors in a research note. Management also continues to seek out assets in the infectious disease space, and believes there are viable assets, the firm notes.
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
